Kolltan Pharmaceuticals
Nov 03, 2016
Medivir & Karo Pharma’s deal; Astellas acquires Ganymed; Celldex Acquires Kolltan; Allergan to Acquire Motus Therapeutics
Medivir entered into an agreement with Karo Pharma to sell its subsidiary BioPhausia Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt free basis, including a normalized working capital, with the transaction expec...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
